CDK4/6 inhibitor plus hormone therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75, with breast cancer that is hormone receptor-positive (HR+) and HER2-negative.
- Your tumor must be measurable on scans and be at a certain stage (like T1c, T2, or T3, with or without lymph node involvement, but not spread to distant organs).
- You must be in good general health (ECOG score 0-1) and have adequate blood counts, kidney, liver, and heart function.
- You cannot have had any prior treatment for this breast cancer (like surgery, chemotherapy, or radiation).
- You must not have other serious health problems like recent heart issues, active infections, or other cancers (except certain cured ones).
- You agree to extra blood tests for ctDNA during the study and to use non-hormonal birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.